Company: BIVIW
Filing Date: 2025-10-06
Form Type: POS AM
Source: 0001520138-25-000294
Chunk: 22

Company: BIOVIE INC.
Filing Date: 2025-10-06
Form: POS AM
Chunk 22
---
Risk Factors” and other cautionary statements made in this prospectus should be read and understood
as being applicable to all related forward-looking statements wherever they appear in this prospectus. The forward-looking statements
contained in this prospectus represent our judgment as of the date of this prospectus. We caution readers not to place undue reliance
on such statements. You should read this prospectus and the documents that we have filed as exhibits to this prospectus and incorporated
by reference herein completely and with the understanding that our actual future results may be materially different from the plans, intentions
and expectations disclosed in the forward-looking statements we make. Except as required by law, we undertake no obligation to update
publicly any forward-looking statements for any reason, even if new information becomes available or other events occur in the future.
All subsequent written and oral forward-looking statements attributable to us or persons acting on our behalf are expressly qualified
in their entirety by the cautionary statements contained above and throughout this prospectus.

| 11 |

<div align='center'>Use of Proceeds</div>

Assuming the exercise of all outstanding Pre-Funded
Warrants and Warrants, we estimate that the net proceeds from this offering will be approximately $15.0 million. There is no assurance
that the holders of the Pre-Funded Warrants or Warrants will elect to exercise any or all of such Pre-Funded Warrants or Warrants. The
exercise price of the Pre-Funded Warrants is $0.0001 per share and the exercise price of the Warrants is $2.50 per share. The likelihood
that holders will exercise their Warrants is highly dependent upon the trading price of our Common Stock. On October 2, 2025, the
last reported sales price of our Common Stock on Nasdaq was $2.00 per share. If the trading price for our Common Stock is less than the
exercise price of the Warrants, we believe holders of the Warrants will be unlikely to exercise their Warrants

We intend to use the net proceeds from this offering,
if any, for working capital and general corporate purposes. This may include, but is not limited to, capital expenditures, research and
development expenditures and acquisitions of new technologies or businesses.

Although we have identified some potential uses of
the net proceeds to be received from this offering, we cannot specify these uses with certainty. The allocations of the proceeds of this
offering presented above constitute the current estimates of our management and are based on our current plans